NA Proactive news snapshot: Gevo Inc, Progressive Planet Solutions Inc, Water Tower Research, Mandalay Resources Corporation, Nextleaf Solutions Ltd, Sonoro Gold Corp, ARMM Inc, Nickel North Exploration Corp, Valeo Pharma Inc UPDATE
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
NA Proactive news snapshot: Nextleaf Solutions Ltd, Sonoro Gold Corp, ARMM Inc, Nickel North Exploration Corp, Valeo Pharma Inc UPDATE
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
NA Proactive news snapshot: Vejii Holdings Ltd, Hapbee Technologies Inc, i-80 Gold Corp, XPhyto Therapeutics Corp, Evergold Corp, DGTL Holdings Inc
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
NIH Pauses Anticoagulant Trial For Critically Ill COVID-19 Patients
Therapeutic anticoagulation trials is looking at which blood thinners are best to use to treat COVID-caused venous thrombosis embolism (VTE)
Thrombus formation in the aortic arch in a 46-year-old COVID patients in the ICU. Three trials are underway to find which anticoagulant strategy is best to treat moderate and critically ill patients where COVID-causes venous thrombo-embolism (VTE) is a major cause of complications. Image courtesy of Margarita Revzin et al.
December 23, 2020 Three clinical trial platforms working together to test the effects of full doses of anticoagulants in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19 (SARS-CoV-2) patients requiring intensive care unit (ICU) support, therapeutic anticoagulation drugs did not reduce the need for organ support. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.